Navigation Links
First study to show how immune cells 'speak' to each other in vivo

Researchers at the Board of Governors' Gene Therapeutics Research Institute at Cedars-Sinai Medical Center have confirmed the existence of anatomical structures that channel information exchanges between a T cell and its target, an antigen-presenting brain cell, in laboratory rats. This immunologic synapse, or junction where signals are shuttled between two immune cells, has previously only been observed in cell cultures, in part because of the limitations of imaging and the rapid, touch-and-go nature of the communication itself.

According to the researchers, this work should settle the controversy over the existence and functional significance of mature immunological synapses in vivo during antiviral immune responses. The findings will allow further experimental exploration of immunological synaptic function during normal and pathological immune responses in vivo.

The full study can be accessed at www.jem.org.

WHY:

The mechanism of how immunological synapses "speak" to each other in vivo has not been observed prior to this research. Although formal proof of this awaits the development of drugs or mutations that interfere selectively with synapse formation, the confirmation of these cellular structures increases the understanding of the immune system and paves the way for further research on the body's immune response system. New knowledge in this area may ultimately improve treatment for immune disorders such as MS, cancer, and AIDS.

WHO:

Pedro Lowenstein, M.D., Ph.D., co-director, Board of Governors' Gene Therapy Research Institute, Cedars-Sinai Medical Center and principal investigator of this study, is available for interviews.


'"/>

Source:Cedars-Sinai Medical Center


Page: 1

Related biology news :

1. Timing is everything: First step in protein building revealed
2. Emory Eye Center Implants Its First Retinal Chips In Patients With Retinitis Pigmentosa
3. First atlas of key brain genes could speed research on cancer, neurological diseases
4. First-ever Compounds To Target Only Metastatic Cells Are Highly Effective Against Breast, Prostate, And Colon Cancers
5. NYCs First Rapid HIV Drug-resistant AIDS Case Prompts Call to Step Up HIV Prevention
6. First real-time view of developing neurons reveals surprises, say Stanford researchers
7. Breast-Cancer Risk Linked to Exposure to Traffic Emissions at Menarche, First Birth
8. Mayo Clinic Researchers Create Obedient Virus; First Step To Use Measles Virus Against Cancer
9. First frozen egg baby born in Canada
10. Human Cells Filmed Instantly Messaging for First Time
11. First North American Encapsulated Islet Transplant without Long-term Immune Suppression into a Patient with Type 1 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/7/2017)... , February 7, 2017 Ipsidy ... Solutions Corporation [OTC: IDGS], ("Ipsidy" or the "Company") a ... transaction processing services, is pleased to announce the following ... Effective January 31, 2017, Philip D. ... Directors, CEO and President.  An experienced payment industry professional ...
(Date:2/2/2017)... NEW YORK , Feb. 2, 2017  EyeLock ... has released a new white paper " What You ... The problem of ensuring user authenticity is a ... protect the authentication of users. However, traditional authentication schemes ... Biometric authentication offers an elegant ...
(Date:1/26/2017)... CITY , Jan. 26, 2017  Crossmatch, a ... unveiled a new solution aimed at combatting fraud, waste ... solution was introduced at the Action on Disaster Relief ... key meeting point for UN agencies and foreign assistance ... Fraud, waste and abuse are a largely unacknowledged ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... ... ... Delpor, Inc. (Delpor), a biotechnology company focused on drug delivery, today announced ... for the further advancement of the company’s 3-month olanzapine product ( DLP-119 ). The ... therapeutic levels of olanzapine for a period of 3 months., “We are honored and ...
(Date:2/24/2017)... , Feb. 24, 2017 Symic Bio, ... developing a new category of therapeutics, announced today the ... SB-030 in peripheral artery disease. The trial will evaluate ... single-use therapeutic, in the reduction of restenosis following angioplasty. ... critical development milestone for SB-030," said Nathan Bachtell ...
(Date:2/24/2017)... Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading ... financial results for the fourth quarter and fiscal year of ... Total sales in the fourth quarter of ... 13.6% in USD terms to $77.6 million from $68.3 million ... profit increased by 13.3% to $46.8 million from $41.3 million ...
(Date:2/23/2017)... 2017 ... share data, unaudited)Three Months Ended December 31,Twelve Months Ended ... $           ... 89026%Aldurazyme Net Product Revenue 3539(10)%9498(4)%Kuvan ... Product Revenue  756025%297303(2)%Vimizim Net Product ...
Breaking Biology Technology: